Literature DB >> 31895090

Discrepant Perception of Lupus Disease Activity: A Comparison Between Patients' and Physicians' Disease Activity Scores.

Claudia Elera-Fitzcarrald, Karen Vega, Rocío V Gamboa-Cárdenas1, Katiuska Zúñiga, Mariela Medina1, Victor Pimentel-Quiroz1, César Pastor-Asurza1, Risto Perich-Campos1, Zoila Rodríguez Bellido1, Russell Griffin2, Cynthia Aranow3, Graciela S Alarcón, Armando Calvo, Manuel F Ugarte-Gil.   

Abstract

OBJECTIVE: The aim of this study was to compare patient and physician (MD) assessment of disease activity in systemic lupus erythematosus patients.
METHODS: This cross-sectional study was conducted between August 2016 and December 2017 at 2 Peruvian hospitals. One group assessed disease activity using a visual analog scale (VAS, 0-100 mm) and the other one using a numerical rating scale (NRS, 0-4), before and after their MD's visit. MDs assessed it with the Mexican Systemic Lupus Erythematosus Disease Activity (Mex-SLEDAI) (0-32) and with the SLICC/ACR Damage Index (SDI) for damage. Health-related quality of life was ascertained with the LupusQoL. Visual analog scale and NRS were compared using the Wilcoxon signed-rank test and the correlation between disease activity as assessed by the patient and the Mex-SLEDAI, SDI, and LupusQoL with the Spearman rank correlation.
RESULTS: Two hundred forty patients were included; mean (SD) age at diagnosis was 34.9 (12.9) years; most patients were Mestizo. Disease duration was 10.1 (7.0) years. The Mex-SLEDAI was 1.9 (2.7) and the SDI 1.2 (1.5). Disease activity as assessed by the patient, either by VAS or NRS, did not correlate with the Mex-SLEDAI or the SDI. In contrast, patient assessment of disease activity, by VAS or NRS, significantly correlated with several components of the LupusQoL (physical health, pain, planning, emotional health, and fatigue).
CONCLUSIONS: Physician's and patient's assessments of disease activity are discrepant; overall, patients score higher than their MDs. Patients score how they perceive the disease is affecting them, rather than disease activity per se. The VAS could be more useful than the NRS as a measurement of disease activity.

Entities:  

Mesh:

Year:  2020        PMID: 31895090     DOI: 10.1097/RHU.0000000000001267

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  5 in total

1.  Patterns of lung diseases predict survival in patients with MPO-ANCA-associated vasculitis: a single-center retrospective study.

Authors:  Shuqiao Yang; Dandan Chai; Yihua Li; Yuanying Wang; Xi Zhan; Liming Zhang; Jing Wang; Qiao Ye
Journal:  Clin Rheumatol       Date:  2021-11-27       Impact factor: 2.980

2.  The use of patient-reported outcome measures to classify type 1 and 2 systemic lupus erythematosus activity.

Authors:  Amanda M Eudy; Bryce B Reeve; Theresa Coles; Li Lin; Jennifer L Rogers; David S Pisetsky; Lisa G Criscione-Schreiber; Jayanth Doss; Rebecca Sadun; Kai Sun; Megan Eb Clowse
Journal:  Lupus       Date:  2022-03-28       Impact factor: 2.858

3.  Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort.

Authors:  Manuel Francisco Ugarte-Gil; Rocio Violeta Gamboa-Cardenas; Cristina Reátegui-Sokolova; Victor Román Pimentel-Quiroz; Mariela Medina; Claudia Elera-Fitzcarrald; Francisco Zevallos; Cesar Augusto Pastor-Asurza; Federico Zazzetti; Chetan S Karyekar; Graciela S Alarcón; Risto Alfredo Perich-Campos
Journal:  Lupus Sci Med       Date:  2022-03

Review 4.  A glimpse into the future of systemic lupus erythematosus.

Authors:  Martin Aringer; Marta E Alarcón-Riquelme; Megan Clowse; Guillermo J Pons-Estel; Edward M Vital; Maria Dall'Era
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-03-30       Impact factor: 5.346

5.  What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.

Authors:  Richard Furie; Eric F Morand; Ian N Bruce; David Isenberg; Ronald van Vollenhoven; Gabriel Abreu; Lilia Pineda; Raj Tummala
Journal:  Arthritis Rheumatol       Date:  2021-09-22       Impact factor: 10.995

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.